第一金融网主办
»您现在的位置: 第一金融网 >> 金融焦点 >> 文传商讯 >> 正文

Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients

2018/12/7 14:27:44  文章来源:文传商讯  作者:文传商讯
文章简介: EntersintoclinicalcollaborationwithVBIVaccinesandexpandspartnershipwithVirBiotechnology;usingmultiplemodalitiestobringafunctionalcurefo

Enters into clinical collaboration with VBI Vaccines and expands partnership with Vir Biotechnology; using multiple modalities to bring a functional cure for hepatitis B to the greater China region
Initiates discovery alliance for novel immunotherapeutics with WuXi Biologics and Tsinghua University
Establishes R&D headquarters in Beijing to broaden partnership capabilities and access to talent

BEIJING & DURHAM, N.C. -- (BUSINESS WIRE) --

Brii Biosciences, a company committed to serving patients’ needs and improving public health in China, today announced several research collaborations that significantly advance its efforts to develop innovative medicines to meet the unique needs of patients in China. These collaborations include two clinical development programs focused on hepatitis B virus (HBV) infection and China-based exclusive research agreements to develop novel immunotherapeutics to treat infectious diseases and other immune dysfunctions. In addition, the company has formally established its research and development headquarters in Beijing and has forged a public-private partnership to promote public health and develop translational research capabilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181206005083/en/

“The greater China region has very specific healthcare needs, and we are intentionally building Brii Bio to address those needs through a mutually beneficial partnership model that provides positive impact on patient health and growth opportunities for our partners,” said Zhi Hong, Ph.D., co-founder and CEO of Brii Bio. “Most significantly, the collaborations announced today catapult us to a leading position in the race to deliver a functional cure for chronic hepatitis B infection in China, where the disease is a significant public health issue and silent epidemic affecting more than 90 million citizens. Our research for novel immune therapies in China is specifically intended to address diseases prevalent in the region.”

Advancing a Functional Cure for Hepatitis B

Brii Bio has entered into agreements with VBI Vaccines and Vir Biotechnology focused on bringing a functional cure for HBV to patients in China.

  • Brii Bio has licensed greater China rights for a novel recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines (NASDAQ: VBIV). VBI-2601 has the potential to induce and sustain broad and effective immune control of chronic HBV infection. Brii Bio plans to initiate clinical proof of concept studies in China in 2019. In addition to the license agreement, Brii Bio has made an equity investment in VBI Vaccines. Details of this transaction were announced by VBI Vaccines today.
  • Brii Bio and Vir Biotechnology have agreed to commence clinical development efforts in China for VIR-2218, a novel, investigational RNA interference (RNAi) therapeutic designed to inhibit expression of all HBV proteins, including hepatitis B surface antigen (HBsAg). Viral protein knockdown may help restore the patient’s own immune response to HBV, thereby offering people living with chronic HBV the potential for a functional cure. This is the first asset that Brii Bio will take into the clinic as part of its existing partnership with Vir in infectious disease, under which Brii Bio will develop and commercialize up to four assets from Vir’s pipeline. VIR-2218 was originated by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) as ALN-HBV02 and was licensed to Vir, which will conduct its clinical development.

Jeff Baxter, president and CEO of VBI, commented: “Partnering with Brii Bio provides a unique opportunity for us to develop a novel therapeutic with a company completely focused on the Chinese healthcare market and we believe this collaboration gives us a strategic advantage to leverage our technology against a significant global health need.”

Hepatitis B virus infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. The burden of HBV in China is the highest in the world, with more than one-third of the world’s 257 million people with chronic HBV living in the country.

Novel Immunotherapeutics for Infectious Diseases

Brii Bio has entered into exclusive research collaborations with WuXi Biologics (2269.HK) and Tsinghua University Institute for Immunology, a world-class academic research institute in Beijing, to discover and develop bispecific antibodies to treat infectious diseases and other immunologic disorders. Brii Bio will retain global rights of all products arising from these collaborations.

  • Brii Bio and WuXi Biologics, a leading global open-access biologics technology platform company, have entered into a discovery collaboration that will give Brii Bio access to WuXi Biologics’ end-to-end biopharmaceutical technology platforms and capabilities. This collaboration will enable discovery, development, and manufacture of biologic products in China.
  • Brii Bio and Tsinghua University will collaborate on China-based innovation for novel immunotherapeutics building on Tsinghua’s world-class expertise in immunology. Tsinghua investigators will provide laboratory facilities, bespoke assays, and deep immunology expertise. Brii Bio will sponsor a joint post-doctoral fellowship with Tsinghua University and provide discovery insight for novel immune therapies.

“In China, there is a great need to improve the treatment of infectious diseases and a vast opportunity to transform care for patients through therapies that inhibit or modulate the host immune responses,” said Professor Chen Dong, Dean of the School of Medicine and Director of the Institute for Immunology at the Tsinghua University. “We are delighted to embark on a research program that leverages WuXi’s leading-edge capabilities and Brii Bio’s target insight so that we can bring forward innovative immune therapies that may reach millions of people in our country and beyond.”

Effective treatments for infectious diseases and immunologic disorders are a significant unmet need in China.

Beijing-based Global Research Hub

Brii Bio has forged a public-private partnership that will focus on the promotion of public health and development of translational research capabilities in Beijing. Brii Bio is building a state-of-the-art facility in the Haidian District that, once complete, will house the company’s research and development operations and up to 200 employees. Establishing a strong presence in Beijing provides Brii Bio with operational efficiencies, proximity to agencies and organizations located in the capital city, and access to the deep research talent base at top universities. As part of this collaboration, the Beijing Commission of Science & Technology and Haidian District will help to coordinate local resources, provide operational efficiency and policy benefits and Brii Bio will co-fund and advise translational research with Tsinghua University School of Medicine and discovery incubators with Tsinghua Industrial R&D Institute.

About Brii Biosciences

Brii Biosciences (Brii Bio) is a company committed to serving patients’ needs and improving public health in China. Founded in early 2018 with operations in the People’s Republic of China and the United States, the company focuses on accelerating innovation and optimizing access to the latest medicines for Chinese patients. Brii Bio helps global partners drive growth and improve return on investment through better understanding of Chinese healthcare systems and access to the wrld’s second largest pharmaceutical market. The company’s focus is treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. For more information, visit www.briibio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181206005083/en/

CONTACT:

Scient PR
Lindy Devereux, +1-646-515-5730, lindy@scientpr.com

Zhi Hong, Ph.D., co-founder and CEO, Brii Biosciences (Photo: Business Wire)

分享到:
第一金融网免责声明:
1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一金融网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
发表评论

【发表评论】(网友评论内容只代表网友观点,与本站立场无关!)
 姓 名:
 评 分: 1分 2分 3分 4分 5分
 评论内容:
验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  2019年中国放假安排出炉:五一小长假没了
     华为CFO孟晚舟加拿大被捕,中国外交部一连回应9
    [银行]  招商银行官微因“锦鲤”活动诱导关注被罚
     中国国有五大行前三季净利增速超5% 股份行资产质
    [股票]  乐视网回应亿元财产冻结:要求贾跃亭以FF抵债
     乐视系近亿元资产被查封 乐视网7次被列为失信被
    [基金]  又一研究员猝亡年仅36岁 基金从业10年刚入券商3
     十大基金纵论A股后市策略:积极政策效果逐步显现
    [保险]  重疾险销售理赔套路起底:广告噱头多 理赔看心情
     郭树清:加大保险资金财务性和战略性投资优质上
    [期货]  郑州商品交易所:将积极筹备红枣、尿素等期货品
     原油期货上市带火原油场外期权
    [股评]  明日最具爆发力六大黑马(12/7)
     7日机构强推买入 六股成摇钱树(12/7)
    [港股]  腾讯:《王者荣耀》实现境内公安实名校验
     与恒大战不休?贾跃亭再申请剥夺时颖资产抵押权
    [美股]  美成长趋缓和贸易战疑虑 美股暴跌逾3%
     美股大反弹:道指迎近8个月以来最大单日涨幅 纳
    [外汇]  人民币对美元中间价“九连跌” 创逾一年半最低
     六大投行最新预测:一文看清混乱市场下的外汇趋
    [债券]  十月地方政府债发行2560亿 今年专项债额度发行接
     时隔5年 200亿央票重出江湖 人民币空头颤抖吧
    [黄金]  感恩节假期来临、谨防黄金破位 机构日内最新交易
     避险升温金价1233美元十周高
    [理财]  《战狼2》主演吴京被揭也得补税
     香港荣登全球最受欢迎旅游城市榜首,深圳位列第
    [信托]  前9月中国房企信托及发债超万亿人民币 “换马甲
     信托部负责人解读信托细则:明确过渡期内信托业
    [房产]  王健林好友¥35亿卖掉万达商管1.5%股权 永辉超市
     中国26家房企销售已超千亿人民币 资产证券化融资
    [汽车]  全新一代唐五座版下线  双十一预售年底上市
     宇通T7新车型上市 售48.58-78.58万元
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2017 afinance.cn All Rights Reserved 版权所有·第一金融网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以第一金融网名义做股票推荐的行为均属违法!

    广告商的言论与行为均与第一金融网无关!股市有风险,投资需谨慎。

    合作邮箱:fengyueyoubian@sina.com 合作电话:18678839953 点击这里给我发消息